A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

NCT01932333 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-40411813 50 mg
DRUG: JNJ-40411813 100 mg
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.